Zentiva's Commitment to a Sustainable Future
Zentiva, a leading pharmaceutical company, recently released its 2025 Sustainability Report, marking another year of significant contributions to public health and environmental stewardship. The report outlines various advancements made by the company throughout the year, presenting a clear message: business growth can align with sustainable practices. In fact, Zentiva was able to cut emissions by 10% within its operations, all while experiencing an increase in net sales and EBITDA.
Key Goals and Achievements
In this report, Zentiva highlights its ambitious goals set in collaboration with the Science Based Targets initiative (SBTi). The commitment includes a significant reduction of 63% in Scope 1, 2, and 3 emissions by 2034, and achieving net-zero emissions by 2050. Among the major accomplishments in 2025 are the following:
- - Renewable Energy Usage: An impressive 83% of the electricity utilized by Zentiva across its operations now derives from renewable sources, with a full 100% in its European manufacturing sites.
- - Water Conservation: The volume of water recycled and reused nearly doubled between 2021 and 2025, demonstrating a clear focus on sustainable resource management.
- - Waste Management: Zentiva successfully diverted 47% of its waste from disposal through reuse, recycling, and repurposing.
- - Biodiversity Initiatives: The company planted over 130,000 trees to aid in reforestation efforts and adopted 3.5 million bees, aiming to enhance biodiversity and fulfill its role as a responsible corporate citizen.
- - Community Projects: Over 120 community-focused projects were implemented in Europe and India, promoting a message of support and solidarity.
Recognition and Awards
Zentiva's sustainability endeavors have not gone unnoticed. The company was honored with a Gold medal from EcoVadis, placing it in the top 2% of the pharmaceutical sector concerning sustainability practices. This recognition further emphasizes the importance of transparency and accountability in corporate sustainability reporting, highlighted by a Transparency Award 2025 from EUPD Group.
Leadership Insights
CEO Steffen Saltofte commented on the significance of Zentiva's role in public health, stating, "As one of Europe's leading manufacturers of off-patent medicines, we carry a responsibility to support public-health systems while reducing our impact on the planet." He continues, noting that the millions who depend on affordable and accessible medicines demonstrate the interconnectedness of corporate foundations and community well-being.
Ines Windisch, Head of Corporate Affairs and Sustainability at Zentiva, added, "Our 2025 Sustainability Report illustrates how our daily actions contribute to healthier communities and a healthier environment. Protecting people and the planet goes hand in hand. Sustainability is a continuous commitment we need to embrace every day, in everything we do."
The Importance of Off-Patent Medicines
As a significant player in the off-patent medicines market, Zentiva is vital for enabling access to high-quality healthcare across Europe. Off-patent medicines account for about 70% of dispensed medications in the region yet represent only 19% of pharmaceutical spending. Such statistics underscore their essential role in the affordability and sustainability of health systems.
Conclusion
Zentiva's ongoing investment in its manufacturing infrastructure and sustainability initiatives ensures that patients can continue to rely on the constant availability of essential medicines. The insights shared in the 2025 Sustainability Report reflect a deep commitment towards impactful practices in both corporate and environmental responsibilities. To learn more about Zentiva's sustainability actions and initiatives, the 2025 Sustainability Report is available at
Zentiva's sustainability webpage.
With these progressive steps, Zentiva is setting a precedent for how pharmaceutical companies can operate while keeping sustainability at the forefront of all their business practices.